Cloud Banner

Medical Devices

Image

Global Pharmacogenetics Testing in Psychiatry/Depression Market – Industry Trends and Forecast to 2031

  • Medical Devices
  • Published Report
  • Mar 2024
  • Global
  • 350 Pages
  • No of Tables: 977
  • No of Figures: 48

Global Pharmacogenetics Testing in Psychiatry/Depression Market, By Type (Anxiety, Depression, Mood Disorders, Bipolar Disorders, Eating Disorders, and Psychotic Disorders), Product (Consumables, Instruments, and Software and Services), Test Type (Whole Genome Sequencing and Chromosomal Array Based Tests), Gene Type (CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and Others), Patient Type (Adult, Geriatric, and Child), End User (Hospital and Clinics, Diagnostics Laboratories, Academic and Research Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distribution, Hospital Pharmacy, and Others) - Industry Trends and Forecast to 2031.

Pharmacogenetics Testing in Psychiatry/Depression Market

Pharmacogenetics Testing in Psychiatry/Depression Market Analysis and Insights

The increasing number of patients suffering from psychiatry and depression disorders is expected to drive market growth. The rising demand for personalized and precision medicine is helping to boost the market growth. The lack of skilled medical and genomic experts and lack of strong clinical evidence may hamper the market growth. However, the rising technological advancements are expected to act as an opportunity for market growth.

Pharmacogenetics Testing in Psychiatry/Depression Market

Pharmacogenetics Testing in Psychiatry/Depression Market

Data Bridge Market Research analyzes that the global pharmacogenetics testing in psychiatry/depression market is expected to reach USD 2.66 billion by 2031 from USD 1.22 billion in 2023, growing with a CAGR of 10.4% in the forecast period of 2024 to 2031.

Report Metric

Details

Forecast Period

2024 to 2031

Base Year

2023

Historic Years

2022 (Customizable to 2016–2021)

Quantitative Units

Revenue in USD Billion and Volume in Units

Segments Covered

Type (Anxiety, Depression, Mood Disorders, Bipolar Disorders, Eating Disorders, and Psychotic Disorders), Product (Consumables, Instruments, and Software and Services), Test Type (Whole Genome Sequencing and Chromosomal Array Based Tests), Gene Type (CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and Others), Patient Type (Adult, Geriatric, and Child), End User (Hospital and Clinics, Diagnostics Laboratories, Academic and Research Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distribution, Hospital Pharmacy, and Others)

Countries Covered

U.S., Canada, Mexico, Germany, U.K., France, Italy, Netherlands, Spain, Russia, Switzerland, Turkey, Poland, Norway, Hungary, Austria, Ireland, Lithuania, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, U.A.E., Israel, South Africa, Egypt, and Rest of Middle East and Africa

Market Players Covered

Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., Sonic Healthcare Limited, QIAGEN, AB-BIOTICS S.A., BiogeniQ Inc., Castle Bioscience Inc., Coriell Life Sciences, Dynamic DNA Laboratories, Eurofins Scientific, Genelex, Genewiz, Genomind Inc., GenXys, HealthSpek, HudsonAlpha, MD Labs, ONEOME LLC, and PacBio among others

Market Definition

Pharmacogenetics testing studies the interaction between the drug and the gene response of a person and searches for the gene variation that is responsible for influencing the drug effect. The test is gaining high demand as many researchers and scientists identified the unique interaction between drugs and individual genes and provides valuable insights that subsequently be used to develop customized or personalized medication.

Pharmacogenetics Testing in Psychiatry/Depression Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:     

Drivers

  • Rising Number of Population Suffering from Depressive Disorder

Depression is a prevalent condition globally that varies from normal mood changes. Depression can become a serious health condition of mild to extreme severity, affecting the person to suffer greatly, and can lead to suicide in the worst cases. While over 45 antidepressants are available, suboptimal response poses difficulty and is considered to be a result of genetic variation.

With the rising prevalence of depression, the demand for pharmacogenetics testing is also increasing as it studies the effect of genetic variants to provide tailored treatment, which is driving the market growth.

  • Growing Biotechnology Sector along with Rising Healthcare Expenditure

People are becoming more aware of their health and also there is alertness for preventive healthcare. Emphasis on healthcare is gaining popularity. Awareness of disease and symptoms is essential for screening and early detection of diseases due to advanced technology available in the healthcare system such as advanced testing which helps the healthcare providers and leads to higher survival rates.

The growing biotechnology sector, coupled with rising healthcare expenditure globally, is anticipated to drive the pharmacogenetics testing market in the fields of psychiatry and depression. There is an increased focus on personalized medicine, including pharmacogenetics testing, as biotechnology companies develop innovative testing methods and technologies. This, combined with the rising healthcare expenditure, indicates a growing investment in advanced healthcare solutions that could improve patient outcomes and reduce overall healthcare costs, which is boosting the market growth.

Pharmacogenetics Testing in Psychiatry/Depression Market

Opportunity

  • Advancements in Genetic Testing

The field of healthcare is experiencing rapid technological advancements, particularly in the development of new and sophisticated methods to promote pharmacogenetics testing. These innovative tests utilize advanced genetic testing methods to provide precise results, enabling healthcare providers to tailor treatment regimens more effectively. This advancement presents a significant opportunity for the global pharmacogenetics testing market in psychiatry and depression. As these cutting-edge technologies become more accessible and refined, they have the potential to revolutionize personalized medicine, offering patients more targeted and effective treatments for mental health conditions.

These tests play a crucial role in establishing a meaningful connection between a drug and an individual's genetic profile. This personalized approach aids healthcare providers in selecting the most suitable medications for patients suffering from major depressive disorders and other psychiatric conditions. By leveraging advancements in genetic testing, pharmacogenetics testing can significantly enhance treatment outcomes and improve patient care in psychiatry and depression, which is expected to create an opportunity for market growth.

Restraints/Challenges

  • Insufficient Clinical Validation

With advancements in medical sciences, new testing methods are being increasingly developed to come up with potent drugs that are efficient in treating major depressive disorders. The antidepressants and the antipsychotics used in the treatments can be ineffective. They can help in suggesting the drugs that can be used to treat the disease as per individual patient needs.

Even though having such an advantage, the tests lack a strong clinical basis to completely rely on them. Although studies conducted on small populations have shown promising results, the efficacy of the tests has no evidence on the larger population.

The pharmacogenetics testing in psychiatry does not assess for non-compliance in treatment outcomes. As a result, when the rate of non-adherence increases in the population being considered, the power of the statistics lowers leading to a lack of evidence to prove the efficiency of the tests.

The lack of basis to entirely depend on these tests is a major drawback in the market. The patients would prefer to stick to traditional methods of testing and thus, it is hindering the market growth.

  • Rising Concern Regarding Data Privacy and Security

Pharmacogenetic testing, which analyzes how an individual's genetic makeup influences their response to medications, raises significant concerns about data privacy and security, particularly in the context of global data sharing and storage. Genetic information is inherently personal and can reveal sensitive details about an individual health, including predispositions to certain diseases and responses to specific drugs. As such, there is a heightened risk of this information being misused or improperly accessed if not adequately protected.

A major concern is the risk of genetic discrimination, where individuals could experience negative outcomes in employment or insurance due to their genetic information. Data breaches are another significant risk, particularly as genetic information is increasingly shared across borders for research or clinical purposes. The transfer of data between jurisdictions with differing privacy regulations can further complicate efforts to ensure data security.

Data privacy and security stand out as significant challenges for the global implementation of pharmacogenetic testing in the psychiatry depression market due to the sensitive nature of genetic information, there is a potential risk of misuse or unauthorized access of patients data which they have provided. The sensitive nature of the data can give rise to several issues, which are expected to challenge the market growth.

Recent Developments

  • In February 2024, Myriad Genetics, Inc., a pioneer in genetic testing and precision medicine, has acquired select assets from Intermountain Health's Precision Genomics (IPG) laboratory. This includes the Precise Tumor Test, the Precise Liquid Test, and IPG's CLIA-certified laboratory in St. George, Utah. This acquisition allows Myriad to enhance its tumor profiling offerings and expand its oncology portfolio, which includes hereditary cancer and companion diagnostic testing options
  • In February 2024, QIAGEN announced that it has been recognized for its sustainability efforts by My Green Lab, a non-profit organization focused on promoting sustainability in scientific research. This will enhance QIAGEN's reputation for sustainability, potentially attracting environmentally conscious customers and partners
  • In November 2023, QIAGEN and DNA Labs International collaborated to solve two decades-old cold cases using QIAGEN's ForenSeq Kintelligence System for forensic genetic genealogy, in conjunction with the GEDmatch PRO database. This highlights the effectiveness and increasing adoption of this approach to human identification. This will result in the effectiveness of QIAGEN's forensic genetic genealogy solutions, potentially boosting their adoption and sales in the forensic market
  • In June 2022, Castle Biosciences, Inc, a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. This acquisition would enable to potentially develop a mental health franchise, starting with a test that currently receives Medicare reimbursement for depression
  • In May 2022, Coriell Life Sciences won Second MedTech Breakthrough Award for Genomics Innovation which leads the way in unlocking the power of pharmacogenomics to improve healthcare. the organization’s Corigen Medication Safety Program has been named “Best Overall Genomics Solution” in the 2022 MedTech Breakthrough Awards. The award will give the testing more credibility among the users

Global Pharmacogenetics Testing in Psychiatry/Depression Market Scope

The global pharmacogenetics testing in psychiatry/depression market is segmented into seven notable segments based on type, product, test type, gene type, patient type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

Type

  • Anxiety
  • Depression
  • Mood Disorders
  • Bipolar Disorders
  • Eating Disorders
  • Psychotic Disorders

On the basis of type, the global pharmacogenetics testing in psychiatry/depression market is segmented into anxiety, depression, mood disorders, bipolar disorders, eating disorders, and psychotic disorders.

Product

  • Consumables
  • Instruments
  • Software and Services

On the basis of product, the global pharmacogenetics testing in psychiatry/depression market is segmented into consumables, instruments, and software and services.

Test Type

  • Whole Genome Sequencing
  • Chromosomal Array Based Tests

On the basis of test type, the global pharmacogenetics testing in psychiatry/depression market is segmented into whole genome sequencing and chromosomal array based tests.

Gene Type

  • CYP2C19
  • CYP2C9 and VKORC1
  • CYP2D6
  • HLA-B
  • HTR2A/C
  • HLA-A
  • CYP3A4
  • SLC6A4
  • MTHFR
  • COMT
  • Others

On the basis of gene type, the global pharmacogenetics testing in psychiatry/depression market is segmented into CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and others.

Patient Type

  • Adult
  • Geriatric
  • Child

On the basis of patient type, the global pharmacogenetics testing in psychiatry/depression market is segmented into adult, geriatric, and child.

End User

  • Hospital and Clinics
  • Diagnostics Laboratories
  • Academic and Research Institutes
  • Others

On the basis of end user, the global pharmacogenetics testing in psychiatry/depression market is segmented into hospital and clinics, diagnostics laboratories, academic and research institutes, and others.

Distribution Channel

  • Direct Tender
  • Third Party Distribution
  • Hospital Pharmacy
  • Others

On the basis of distribution channel, the global pharmacogenetics testing in psychiatry/depression market is segmented into direct tender, third party distribution, hospital pharmacy, and others.

Pharmacogenetics Testing in Psychiatry/Depression Market

Global Pharmacogenetics Testing in Psychiatry/Depression Market Regional Analysis/Insights

The global pharmacogenetics testing in psychiatry/depression market is segmented into seven notable segments based on type, product, test type, gene type, patient type, end user, and distribution channel.

The countries covered in this market report are U.S., Canada, Mexico, Germany, U.K., France, Italy, Netherlands, Spain, Russia, Switzerland, Turkey, Poland, Norway, Hungary, Austria, Ireland, Lithuania, rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Malaysia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, U.A.E., Israel, South Africa, Egypt, and rest of Middle East and Africa.

North America is expected to dominate the global pharmacogenetics testing in psychiatry/depression market as increasing number of population suffering from depressive disorder in the region. The U.S. is expected to dominate the North America region because robust initiatives taken by manufacturers due to genetic variability. China is expected to dominate the Asia-Pacific region due to the growing biotechnology sector along with rising healthcare expenditure. Germany is expected to dominate the Europe region due to increasing interest for personalized and precision medication.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Pharmacogenetics Testing in Psychiatry/Depression Market

Global Pharmacogenetics Testing in Psychiatry/Depression Market Competitive Landscape and Share Analysis

The global pharmacogenetics testing in psychiatry/depression market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the global pharmacogenetics testing in psychiatry/depression market.

Some of the major players operating in the market are Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., Sonic Healthcare Limited, QIAGEN, AB-BIOTICS S.A., BiogeniQ Inc., Castle Bioscience Inc., Coriell Life Sciences, Dynamic DNA Laboratories, Eurofins Scientific, Genelex, Genewiz, Genomind Inc., GenXys, HealthSpek, HudsonAlpha, MD Labs, ONEOME LLC, and PacBio among others.


SKU-

TABLE 1 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 2 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 3 GLOBAL CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 4 GLOBAL CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 5 GLOBAL CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 6 GLOBAL INSTRUMENTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 7 GLOBAL SOFTWARE AND SERVICES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 8 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 9 GLOBAL WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 10 GLOBAL WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 11 GLOBAL EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 12 GLOBAL KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 13 GLOBAL LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 14 GLOBAL DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 15 GLOBAL MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 16 GLOBAL CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 17 GLOBAL CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 18 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 19 GLOBAL ANXIETY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 20 GLOBAL DEPRESSION IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 21 GLOBAL MOOD DISORDERS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 22 GLOBAL BIPOLAR DISORDERS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 23 GLOBAL EATING DISORDERS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 24 GLOBAL PSYCHOTIC DISORDERS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 25 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 26 GLOBAL CYP2C19 IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 27 GLOBAL CYP2C9 AND VKORC1 IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 28 GLOBAL CYP2D6 IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 29 GLOBAL HLA-B IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 30 GLOBAL HTR2A/C IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 31 GLOBAL HLA-A IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 32 GLOBAL CYP3A4 IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 33 GLOBAL SLC6A4 IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 34 GLOBAL MTHFR IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 35 GLOBAL COMT IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 36 GLOBAL OTHERS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 37 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 38 GLOBAL ADULT IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 39 GLOBAL GERIATRIC IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 40 GLOBAL CHILD IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 41 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 42 GLOBAL HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 43 GLOBAL HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 44 GLOBAL DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 45 GLOBAL DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 46 GLOBAL ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 47 GLOBAL ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 48 GLOBAL OTHERS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 49 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 50 GLOBAL DIRECT TENDER IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 51 GLOBAL THIRD PARTY DISTRIBUTION IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 52 GLOBAL HOSPITAL PHARMACY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 53 GLOBAL OTHERS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 54 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 55 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 56 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 57 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 58 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 59 NORTH AMERICA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 60 NORTH AMERICA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 61 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 62 NORTH AMERICA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 63 NORTH AMERICA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 64 NORTH AMERICA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 65 NORTH AMERICA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 66 NORTH AMERICA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 67 NORTH AMERICA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 68 NORTH AMERICA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 69 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 70 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 71 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 72 NORTH AMERICA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 73 NORTH AMERICA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 74 NORTH AMERICA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 75 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 76 U.S. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 77 U.S. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 78 U.S. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 79 U.S. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 80 U.S. CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 81 U.S. CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 82 U.S. CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 83 U.S. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 84 U.S. WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 85 U.S. EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 86 U.S. KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 87 U.S. LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 88 U.S. DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 89 U.S. MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 90 U.S. CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 91 U.S. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 92 U.S. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 93 U.S. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 94 U.S. HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 95 U.S. DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 96 U.S. ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 97 U.S. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 98 CANADA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 99 CANADA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 100 CANADA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 101 CANADA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 102 CANADA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 103 CANADA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 104 CANADA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 105 CANADA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 106 CANADA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 107 CANADA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 108 CANADA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 109 CANADA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 110 CANADA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 111 CANADA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 112 CANADA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 113 CANADA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 114 CANADA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 115 CANADA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 116 CANADA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 117 CANADA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 118 CANADA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 119 CANADA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 120 MEXICO PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 121 MEXICO PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 122 MEXICO PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 123 MEXICO PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 124 MEXICO CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 125 MEXICO CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 126 MEXICO CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 127 MEXICO PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 128 MEXICO WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 129 MEXICO EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 130 MEXICO KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 131 MEXICO LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 132 MEXICO DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 133 MEXICO MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 134 MEXICO CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 135 MEXICO PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 136 MEXICO PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 137 MEXICO PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 138 MEXICO HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 139 MEXICO DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 140 MEXICO ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 141 MEXICO PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 142 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 143 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 144 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 145 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 146 EUROPE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 147 EUROPE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 148 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 149 EUROPE WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 150 EUROPE EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 151 EUROPE KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 152 EUROPE LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 153 EUROPE DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 154 EUROPE MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 155 EUROPE CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 156 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 157 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 158 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 159 EUROPE HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 160 EUROPE DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 161 EUROPE ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 162 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 163 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 164 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 165 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 166 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 167 GERMANY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 168 GERMANY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 169 GERMANY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 170 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 171 GERMANY WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 172 GERMANY EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 173 GERMANY KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 174 GERMANY LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 175 GERMANY DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 176 GERMANY MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 177 GERMANY CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 178 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 179 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 180 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 181 GERMANY HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 182 GERMANY DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 183 GERMANY ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 184 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 185 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 186 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 187 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 188 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 189 FRANCE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 190 FRANCE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 191 FRANCE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 192 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 193 FRANCE WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 194 FRANCE EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 195 FRANCE KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 196 FRANCE LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 197 FRANCE DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 198 FRANCE MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 199 FRANCE CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 200 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 201 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 202 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 203 FRANCE HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 204 FRANCE DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 205 FRANCE ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 206 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 207 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 208 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 209 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 210 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 211 U.K. CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 212 U.K. CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 213 U.K. CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 214 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 215 U.K. WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 216 U.K. EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 217 U.K. KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 218 U.K. LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 219 U.K. DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 220 U.K. MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 221 U.K. CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 222 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 223 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 224 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 225 U.K. HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 226 U.K. DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 227 U.K. ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 228 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 229 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 230 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 231 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 232 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 233 ITALY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 234 ITALY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 235 ITALY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 236 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 237 ITALY WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 238 ITALY EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 239 ITALY KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 240 ITALY LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 241 ITALY DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 242 ITALY MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 243 ITALY CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 244 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 245 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 246 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 247 ITALY HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 248 ITALY DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 249 ITALY ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 250 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 251 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 252 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 253 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 254 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 255 RUSSIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 256 RUSSIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 257 RUSSIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 258 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 259 RUSSIA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 260 RUSSIA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 261 RUSSIA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 262 RUSSIA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 263 RUSSIA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 264 RUSSIA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 265 RUSSIA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 266 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 267 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 268 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 269 RUSSIA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 270 RUSSIA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 271 RUSSIA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 272 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 273 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 274 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 275 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 276 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 277 SPAIN CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 278 SPAIN CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 279 SPAIN CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 280 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 281 SPAIN WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 282 SPAIN EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 283 SPAIN KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 284 SPAIN LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 285 SPAIN DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 286 SPAIN MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 287 SPAIN CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 288 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 289 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 290 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 291 SPAIN HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 292 SPAIN DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 293 SPAIN ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 294 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 295 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 296 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 297 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 298 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 299 TURKEY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 300 TURKEY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 301 TURKEY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 302 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 303 TURKEY WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 304 TURKEY EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 305 TURKEY KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 306 TURKEY LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 307 TURKEY DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 308 TURKEY MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 309 TURKEY CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 310 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 311 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 312 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 313 TURKEY HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 314 TURKEY DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 315 TURKEY ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 316 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 317 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 318 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 319 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 320 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 321 NETHERLANDS CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 322 NETHERLANDS CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 323 NETHERLANDS CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 324 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 325 NETHERLANDS WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 326 NETHERLANDS EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 327 NETHERLANDS KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 328 NETHERLANDS LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 329 NETHERLANDS DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 330 NETHERLANDS MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 331 NETHERLANDS CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 332 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 333 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 334 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 335 NETHERLANDS HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 336 NETHERLANDS DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 337 NETHERLANDS ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 338 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 339 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 340 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 341 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 342 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 343 SWITZERLAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 344 SWITZERLAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 345 SWITZERLAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 346 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 347 SWITZERLAND WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 348 SWITZERLAND EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 349 SWITZERLAND KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 350 SWITZERLAND LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 351 SWITZERLAND DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 352 SWITZERLAND MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 353 SWITZERLAND CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 354 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 355 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 356 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 357 SWITZERLAND HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 358 SWITZERLAND DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 359 SWITZERLAND ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 360 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 361 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 362 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 363 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 364 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 365 POLAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 366 POLAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 367 POLAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 368 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 369 POLAND WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 370 POLAND EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 371 POLAND KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 372 POLAND LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 373 POLAND DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 374 POLAND MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 375 POLAND CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 376 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 377 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 378 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 379 POLAND HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 380 POLAND DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 381 POLAND ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 382 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 383 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 384 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 385 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 386 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 387 HUNGARY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 388 HUNGARY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 389 HUNGARY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 390 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 391 HUNGARY WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 392 HUNGARY EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 393 HUNGARY KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 394 HUNGARY LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 395 HUNGARY DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 396 HUNGARY MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 397 HUNGARY CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 398 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 399 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 400 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 401 HUNGARY HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 402 HUNGARY DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 403 HUNGARY ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 404 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 405 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 406 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 407 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 408 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 409 AUSTRIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 410 AUSTRIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 411 AUSTRIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 412 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 413 AUSTRIA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 414 AUSTRIA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 415 AUSTRIA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 416 AUSTRIA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 417 AUSTRIA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 418 AUSTRIA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 419 AUSTRIA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 420 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 421 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 422 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 423 AUSTRIA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 424 AUSTRIA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 425 AUSTRIA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 426 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 427 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 428 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 429 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 430 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 431 NORWAY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 432 NORWAY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 433 NORWAY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 434 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 435 NORWAY WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 436 NORWAY EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 437 NORWAY KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 438 NORWAY LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 439 NORWAY DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 440 NORWAY MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 441 NORWAY CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 442 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 443 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 444 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 445 NORWAY HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 446 NORWAY DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 447 NORWAY ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 448 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 449 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 450 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 451 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 452 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 453 IRELAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 454 IRELAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 455 IRELAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 456 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 457 IRELAND WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 458 IRELAND EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 459 IRELAND KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 460 IRELAND LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 461 IRELAND DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 462 IRELAND MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 463 IRELAND CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 464 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 465 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 466 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 467 IRELAND HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 468 IRELAND DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 469 IRELAND ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 470 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 471 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 472 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 473 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 474 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 475 LITHUANIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 476 LITHUANIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 477 LITHUANIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 478 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 479 LITHUANIA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 480 LITHUANIA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 481 LITHUANIA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 482 LITHUANIA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 483 LITHUANIA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 484 LITHUANIA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 485 LITHUANIA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 486 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 487 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 488 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 489 LITHUANIA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 490 LITHUANIA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 491 LITHUANIA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 492 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 493 REST OF EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 494 ASIA-PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 495 ASIA-PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 496 ASIA-PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 497 ASIA-PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 498 ASIA-PACIFIC CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 499 ASIA-PACIFIC CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 500 ASIA-PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 501 ASIA-PACIFIC WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 502 ASIA-PACIFIC EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 503 ASIA-PACIFIC KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 504 ASIA-PACIFIC LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 505 ASIA-PACIFIC DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 506 ASIA-PACIFIC MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 507 ASIA-PACIFIC CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 508 ASIA-PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 509 ASIA-PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 510 ASIA-PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 511 ASIA-PACIFIC HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 512 ASIA-PACIFIC DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 513 ASIA-PACIFIC ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 514 ASIA-PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 515 JAPAN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 516 JAPAN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 517 JAPAN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 518 JAPAN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 519 JAPAN CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 520 JAPAN CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 521 JAPAN CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 522 JAPAN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 523 JAPAN WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 524 JAPAN EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 525 JAPAN DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 526 JAPAN MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 527 JAPAN CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 528 JAPAN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 529 JAPAN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 530 JAPAN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 531 JAPAN HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 532 JAPAN DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 533 JAPAN ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 534 JAPAN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 535 CHINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 536 CHINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 537 CHINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 538 CHINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 539 CHINA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 540 CHINA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 541 CHINA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 542 CHINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 543 CHINA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 544 CHINA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 545 CHINA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 546 CHINA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 547 CHINA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 548 CHINA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 549 CHINA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 550 CHINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 551 CHINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 552 CHINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 553 CHINA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 554 CHINA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 555 CHINA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 556 CHINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 557 SOUTH KOREA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 558 SOUTH KOREA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 559 SOUTH KOREA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 560 SOUTH KOREA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 561 SOUTH KOREA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 562 SOUTH KOREA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 563 SOUTH KOREA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 564 SOUTH KOREA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 565 SOUTH KOREA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 566 SOUTH KOREA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 567 SOUTH KOREA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 568 SOUTH KOREA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 569 SOUTH KOREA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 570 SOUTH KOREA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 571 SOUTH KOREA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 572 SOUTH KOREA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 573 SOUTH KOREA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 574 SOUTH KOREA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 575 SOUTH KOREA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 576 SOUTH KOREA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 577 SOUTH KOREA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 578 SOUTH KOREA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 579 INDIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 580 INDIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 581 INDIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 582 INDIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 583 INDIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 584 INDIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 585 INDIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 586 INDIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 587 INDIA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 588 INDIA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 589 INDIA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 590 INDIA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 591 INDIA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 592 INDIA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 593 INDIA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 594 INDIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 595 INDIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 596 INDIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 597 INDIA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 598 INDIA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 599 INDIA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 600 INDIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 601 AUSTRALIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 602 AUSTRALIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 603 AUSTRALIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 604 AUSTRALIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 605 AUSTRALIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 606 AUSTRALIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 607 AUSTRALIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 608 AUSTRALIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 609 AUSTRALIA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 610 AUSTRALIA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 611 AUSTRALIA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 612 AUSTRALIA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 613 AUSTRALIA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 614 AUSTRALIA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 615 AUSTRALIA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 616 AUSTRALIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 617 AUSTRALIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 618 AUSTRALIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 619 AUSTRALIA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 620 AUSTRALIA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 621 AUSTRALIA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 622 AUSTRALIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 623 SINGAPORE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 624 SINGAPORE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 625 SINGAPORE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 626 SINGAPORE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 627 SINGAPORE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 628 SINGAPORE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 629 SINGAPORE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 630 SINGAPORE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 631 SINGAPORE WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 632 SINGAPORE EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 633 SINGAPORE KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 634 SINGAPORE LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 635 SINGAPORE DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 636 SINGAPORE MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 637 SINGAPORE CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 638 SINGAPORE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 639 SINGAPORE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 640 SINGAPORE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 641 SINGAPORE HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 642 SINGAPORE DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 643 SINGAPORE ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 644 SINGAPORE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 645 THAILAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 646 THAILAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 647 THAILAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 648 THAILAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 649 THAILAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 650 THAILAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 651 THAILAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 652 THAILAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 653 THAILAND WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 654 THAILAND EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 655 THAILAND KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 656 THAILAND LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 657 THAILAND DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 658 THAILAND MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 659 THAILAND CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 660 THAILAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 661 THAILAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 662 THAILAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 663 THAILAND HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 664 THAILAND DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 665 THAILAND ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 666 THAILAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 667 MALAYSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 668 MALAYSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 669 MALAYSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 670 MALAYSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 671 MALAYSIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 672 MALAYSIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 673 MALAYSIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 674 MALAYSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 675 MALAYSIA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 676 MALAYSIA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 677 MALAYSIA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 678 MALAYSIA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 679 MALAYSIA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 680 MALAYSIA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 681 MALAYSIA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 682 MALAYSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 683 MALAYSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 684 MALAYSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 685 MALAYSIA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 686 MALAYSIA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 687 MALAYSIA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 688 MALAYSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 689 INDONESIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 690 INDONESIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 691 INDONESIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 692 INDONESIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 693 INDONESIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 694 INDONESIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 695 INDONESIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 696 INDONESIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 697 INDONESIA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 698 INDONESIA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 699 INDONESIA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 700 INDONESIA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 701 INDONESIA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 702 INDONESIA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 703 INDONESIA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 704 INDONESIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 705 INDONESIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 706 INDONESIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 707 INDONESIA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 708 INDONESIA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 709 INDONESIA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 710 INDONESIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 711 PHILIPPINES PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 712 PHILIPPINES PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 713 PHILIPPINES PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 714 PHILIPPINES PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 715 PHILIPPINES CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 716 PHILIPPINES CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 717 PHILIPPINES CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 718 PHILIPPINES PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 719 PHILIPPINES WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 720 PHILIPPINES EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 721 PHILIPPINES KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 722 PHILIPPINES LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 723 PHILIPPINES DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 724 PHILIPPINES MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 725 PHILIPPINES CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 726 PHILIPPINES PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 727 PHILIPPINES PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 728 PHILIPPINES PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 729 PHILIPPINES HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 730 PHILIPPINES DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 731 PHILIPPINES ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 732 PHILIPPINES PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 733 VIETNAM PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 734 VIETNAM PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 735 VIETNAM PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 736 VIETNAM PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 737 VIETNAM CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 738 VIETNAM CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME, (UNITS)

TABLE 739 VIETNAM CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 740 VIETNAM PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 741 VIETNAM WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 742 VIETNAM EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 743 VIETNAM KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 744 VIETNAM LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 745 VIETNAM DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 746 VIETNAM MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 747 VIETNAM CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 748 VIETNAM PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 749 VIETNAM PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 750 VIETNAM PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 751 VIETNAM HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 752 VIETNAM DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 753 VIETNAM ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 754 VIETNAM PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 755 REST OF ASIA-PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 756 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 757 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 758 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 759 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 760 MIDDLE EAST AND AFRICA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 761 MIDDLE EAST AND AFRICA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 762 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 763 MIDDLE EAST AND AFRICA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 764 MIDDLE EAST AND AFRICA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 765 MIDDLE EAST AND AFRICA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 766 MIDDLE EAST AND AFRICA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 767 MIDDLE EAST AND AFRICA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 768 MIDDLE EAST AND AFRICA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 769 MIDDLE EAST AND AFRICA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 770 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 771 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 772 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 773 MIDDLE EAST AND AFRICA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 774 MIDDLE EAST AND AFRICA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 775 MIDDLE EAST AND AFRICA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 776 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 777 SOUTH AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 778 SOUTH AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 779 SOUTH AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 780 SOUTH AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 781 SOUTH AFRICA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 782 SOUTH AFRICA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 783 SOUTH AFRICA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 784 SOUTH AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 785 SOUTH AFRICA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 786 SOUTH AFRICA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 787 SOUTH AFRICA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 788 SOUTH AFRICA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 789 SOUTH AFRICA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 790 SOUTH AFRICA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 791 SOUTH AFRICA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 792 SOUTH AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 793 SOUTH AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 794 SOUTH AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 795 SOUTH AFRICA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 796 SOUTH AFRICA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 797 SOUTH AFRICA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 798 SOUTH AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 799 SAUDI ARABIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 800 SAUDI ARABIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 801 SAUDI ARABIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 802 SAUDI ARABIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 803 SAUDI ARABIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 804 SAUDI ARABIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 805 SAUDI ARABIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 806 SAUDI ARABIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 807 SAUDI ARABIA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 808 SAUDI ARABIA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 809 SAUDI ARABIA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 810 SAUDI ARABIA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 811 SAUDI ARABIA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 812 SAUDI ARABIA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 813 SAUDI ARABIA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 814 SAUDI ARABIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 815 SAUDI ARABIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 816 SAUDI ARABIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 817 SAUDI ARABIA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 818 SAUDI ARABIA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 819 SAUDI ARABIA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 820 SAUDI ARABIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 821 U.A.E. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 822 U.A.E. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 823 U.A.E. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 824 U.A.E. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 825 U.A.E. CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 826 U.A.E. CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 827 U.A.E. CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 828 U.A.E. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 829 U.A.E. WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 830 U.A.E. EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 831 U.A.E. KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 832 U.A.E. LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 833 U.A.E. DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 834 U.A.E. MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 835 U.A.E. CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 836 U.A.E. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 837 U.A.E. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 838 U.A.E. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 839 U.A.E. HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 840 U.A.E. DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 841 U.A.E. ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 842 U.A.E. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 843 ISRAEL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 844 ISRAEL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 845 ISRAEL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 846 ISRAEL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 847 ISRAEL CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 848 ISRAEL CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 849 ISRAEL CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 850 ISRAEL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 851 ISRAEL WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 852 ISRAEL EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 853 ISRAEL KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 854 ISRAEL LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 855 ISRAEL DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 856 ISRAEL MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 857 ISRAEL CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 858 ISRAEL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 859 ISRAEL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 860 ISRAEL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 861 ISRAEL HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 862 ISRAEL DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 863 ISRAEL ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 864 ISRAEL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 865 EGYPT PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 866 EGYPT PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 867 EGYPT PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 868 EGYPT PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 869 EGYPT CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 870 EGYPT CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 871 EGYPT CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 872 EGYPT PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 873 EGYPT WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 874 EGYPT EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 875 EGYPT KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 876 EGYPT LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 877 EGYPT DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 878 EGYPT MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 879 EGYPT CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 880 EGYPT PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 881 EGYPT PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 882 EGYPT PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 883 EGYPT HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 884 EGYPT DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 885 EGYPT ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 886 EGYPT PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 887 REST OF MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 888 SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 889 SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 890 SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 891 SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 892 SOUTH AMERICA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 893 SOUTH AMERICA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 894 SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 895 SOUTH AMERICA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 896 SOUTH AMERICA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 897 SOUTH AMERICA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 898 SOUTH AMERICA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 899 SOUTH AMERICA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 900 SOUTH AMERICA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 901 SOUTH AMERICA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 902 SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 903 SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 904 SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 905 SOUTH AMERICA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 906 SOUTH AMERICA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 907 SOUTH AMERICA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 908 SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 909 BRAZIL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 910 BRAZIL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 911 BRAZIL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 912 BRAZIL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 913 BRAZIL CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 914 BRAZIL CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 915 BRAZIL CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 916 BRAZIL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 917 BRAZIL WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 918 BRAZIL EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 919 BRAZIL KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 920 BRAZIL LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 921 BRAZIL DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 922 BRAZIL MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 923 BRAZIL CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 924 BRAZIL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 925 BRAZIL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 926 BRAZIL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 927 BRAZIL HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 928 BRAZIL DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 929 BRAZIL ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 930 BRAZIL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 931 ARGENTINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 932 ARGENTINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 933 ARGENTINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 934 ARGENTINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 935 ARGENTINA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 936 ARGENTINA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 937 ARGENTINA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 938 ARGENTINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 939 ARGENTINA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 940 ARGENTINA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 941 ARGENTINA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 942 ARGENTINA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 943 ARGENTINA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 944 ARGENTINA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 945 ARGENTINA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 946 ARGENTINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 947 ARGENTINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 948 ARGENTINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 949 ARGENTINA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 950 ARGENTINA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 951 ARGENTINA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 952 ARGENTINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 953 PERU PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 954 PERU PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 955 PERU PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 956 PERU PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 957 PERU CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 958 PERU CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 959 PERU CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD)

TABLE 960 PERU PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 961 PERU WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 962 PERU EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 963 PERU KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 964 PERU LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 965 PERU DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 966 PERU MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 967 PERU CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 968 PERU PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND)

TABLE 969 PERU PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 970 PERU PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 971 PERU HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 972 PERU DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 973 PERU ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 974 PERU PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 975 REST OF SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 976 SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS)

TABLE 977 SOUTH AMERICA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The major players in the Pharmacogenetics Testing in Psychiatry/Depression Market are Genelex (Part of Invitae corporation), Genewiz (Part of Azenta Life Sciences), MD Labs, BiogeneiQ, Inc., ONEOME, LLC, Myriad Genetics, Inc., GenXys, Castle Biosciences, Inc., PacBio, QIAGEN, etc.
The Pharmacogenetics Testing in Psychiatry/Depression Market growth rate is 10.4% during the forecast period.
The Pharmacogenetics Testing in Psychiatry/Depression Market growth rate is USD 2.66 billion by 2031 during the forecast period.
The type, product, test type, gene type, patient type, end user, and distribution channel are the factors on which the Pharmacogenetics Testing in Psychiatry/Depression Market research is based.
The latest developments in the Pharmacogenetics Testing in Psychiatry/Depression Market are Myriad Genetics, Inc., a pioneer in genetic testing and precision medicine, has acquired select assets from Intermountain Health's Precision Genomics (IPG) laboratory and QIAGEN announced that it has been recognized for its sustainability efforts by My Green Lab, a non-profit organization focused on promoting sustainability in scientific research.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials